1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Patología Molecular del Cáncer

Patología Molecular del Cáncer

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Solórzano JL, Menéndez V, Parra E, Solis L, Salazar R, García-Cosío M, Climent F, Fernández S, Díaz E, Francisco-Cruz A, Khoury J, Jiang M, Tamegnon A, Montalbán C, Melero I, Wistuba I, De Andrea C, F García J.

    Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma.

    ONCOIMMUNOLOGY . 13(1): 2388304-2388304.

    [doi:10.1080/2162402X.2024.2388304]

  • Martínez-Campelo L, Blanco-Verea A, López-Fernández T, Martínez-Monzonís A, Buño A, Mazón P, Zamora P, Norton N, Reddy JS, Velasco-Ruiz A, González-Neira A, Vulsteke C, Alonso-Gordoa T, Cruz R, Diz-de Almeida S, Carracedo A, González-Juanatey JR, López-Sendón J, Brion M.

    Meta-analysis of genome-wide association studies for cancer therapy-related cardiovascular dysfunction and functional mapping highlight an intergenic region close to TP63.

    SCIENTIFIC REPORTS . 14(1): 18413-18413.

    [doi:10.1038/s41598-024-69064-5]

  • Riesco-Martinez MC, Capdevila J, Alonso V, Jimenez-Fonseca P, Teule A, Grande E, Sevilla I, Benavent M, Alonso-Gordoa T, Custodio A, Anton-Pascual B, Hernando J, Polo E, Castillo-Trujillo OA, Lamas-Paz A, Teijo A, Rodriguez-Gil Y, Soldevilla B, Garcia-Carbonero R.

    Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).

    NATURE COMMUNICATIONS . 15(1): 6753-6753.

    [doi:10.1038/s41467-024-50969-8]

  • Albarrán V, Guerrero P, de Quevedo CG, González C, Chamorro J, Rosero DI, Moreno J, Calvo JC, de Aguado PP, Alía V, Sotoca P, Barrill AM, Román MS, Álvarez-Ballesteros P, Serrano JJ, Soria A, Olmedo ME, Saavedra C, Cortés A, Gómez A, Lage Y, Ruiz Á, Ferreiro MR, Longo F, Garrido P, Gajate P.

    Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent.

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 73(10): 186-186. Nº de citas: 2

    [doi:10.1007/s00262-024-03772-9]

  • Perez-Navarro E, Conteduca V, Funes JM, Dominguez JI, Martin-Serrano M, Cremaschi P, Fernandez-Perez MP, Gordoa TA, Font A, Vázquez-Estévez S, González-Del-Alba A, Wetterskog D, Mellado B, Fernandez-Calvo O, Méndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez Sanchez A, Santander C, Sáez MI, Puente J, Tudela J, Marinas C, López-Andreo MJ, Castellano D, Attard G, Grande E, Rosino A, Botia JA, Palma-Mendez J, De Giorgi U, Gonzalez-Billalabeitia E.

    Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer.

    Cancers . 16(14): .

    [doi:10.3390/cancers16142535]

  • Rubio MJ, Manzano A, de Sande LM, Estévez-García P, Gordon MDM, de Prado DS, de Aranguiz BHF, Guerra-Alia EM, Carbó-Bagué A, Romero I, Corbellas M, González-Haba A, Robles-Barraza CE, Martínez-García J, González-Martín A.

    Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study.

    Bmc Cancer . 24(1): 803-803.

    [doi:10.1186/s12885-024-12577-z]

  • Araujo-Castro M, Biagetti B, Menéndez Torre E, Novoa-Testa I, Cordido F, Pascual-Corrales E, Rodríguez Berrocal V, Guerrero-Pérez F, Vicente A, Percovich Hualpa JC, García-Centeno R, González-Fernández L, Ollero García MD, Irigaray Echarri A, Moure Rodríguez MD, Novo-Rodríguez C, Calatayud M, Villar-Taibo R, Bernabéu I, Alvarez-Escola C, Benítez Valderrama P, Tenorio-Jiménez C, Abellán Galiana P, Venegas E, González-Molero I, Iglesias P, Blanco-Carrera C, Vidal-Ostos De Lara F, de Miguel Novoa P, López Mezquita E, Hanzu FA, Aldecoa I, Aznar S, Lamas C, Aulinas A, Asla Q, Gracia Gimeno P, Recio-Córdova JM, Avilés-Pérez MD, Asensio-Wandosell D, Sampedro-Núñez M, Cámara R, Paja Fano M, Ruz-Caracuel I, Fajardo C, Marazuela M, Puig-Domingo M.

    Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs.

    ENDOCRINE-RELATED CANCER . 31(7): . Nº de citas: 3

    [doi:10.1530/ERC-24-0043]

  • Martínez-Jañez N, Ezquerra MB, Manso Sanchez LM, Carrasco FH, Torres AA, Morales S, Ortega PT, Gil VLO, Sampedro T, Conejero RA, Calvo-Martinez L, Galve-Calvo E, López R, de la Pena FA, Lopez-Tarruella S, de Araguiz BAHF, Ruiz LB, Cardenas TM, Chacon JI, Antón FM.

    First-line therapy with palbociclib in patients with advanced HR(+)/HER2(-) breast cancer: The real-life study PALBOSPAIN.

    BREAST CANCER RESEARCH AND TREATMENT . 206(2): 317-328.

    [doi:10.1007/s10549-024-07287-w]

  • Menéndez V, Solórzano JL, García-Cosío M, Cereceda L, Díaz E, Estévez M, Roncador G, Vega Z, Montalbán C, Kulasinghe A, García JF.

    Mapping the spatial dynamics of the CD4+ T cell spectrum in classical Hodgkin lymphoma.

    MODERN PATHOLOGY . 37(9): 100551-100551. Nº de citas: 2

    [doi:10.1016/j.modpat.2024.100551]

  • Colomer R, González-Farré B, Ballesteros AI, Peg V, Bermejo B, Pérez-Mies B, de la Cruz S, Rojo F, Pernas S, Palacios J.

    Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

    CLINICAL & TRANSLATIONAL ONCOLOGY . 26(12): 2935-2951.

    [doi:10.1007/s12094-024-03541-1]

  • Biagetti B, Araujo-Castro M, Torre EM, Novoa-Testa I, Cordido F, Corrales EP, Berrocal VR, Guerrero-Pérez F, Vicente A, Percovich JC, Centeno RG, González L, García MDO, Echarri AI, Rodríguez MDM, Novo-Rodríguez C, Calatayud M, Villar-Taibo R, Bernabéu I, Alvarez-Escola C, Valderrama PB, Tenorio-Jiménez C, Galiana PA, Moreno EV, Molero IG, Iglesias P, Blanco C, De Lara FV, de Miguel P, Mezquita EL, Hanzu F, Aldecoa I, Aznar S, Lamas C, Aulinas A, Asla Roca Q, Gracia P, Córdova JMR, Aviles M, Asensio-Wandosel D, Sampedro M, Cámara R, Paja M, Ruz-Caracuel I, Fajardo-Montañana C, Asanza EC, Martinez-Saez E, Marazuela M, Puig-Domingo M.

    Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion.

    EUROPEAN JOURNAL OF ENDOCRINOLOGY . 190(6): 458-466.

    [doi:10.1093/ejendo/lvae053]

  • Alonso-Gordoa T, Goodman M, Vulsteke C, Roubaud G, Zhang J, Parikh M, Piulats JM, Azaro A, James GD, Cavazzina R, Gangl ET, Thompson J, Pouliot G, Kumar R, Sweeney C.

    A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer.

    ESMO open . 9(6): 103446-103446.

    [doi:10.1016/j.esmoop.2024.103446]

  • Makker V, Perez-Fidalgo JA, Valabrega G, Hamilton E, Van Gorp T, Sehouli J, Reginácová K, Richardson DL, Perri T, Oza AM, Miller DS, Alía EMG, De Giorgi U, Henry S, Spitz DL, Wimberger P, Bednaríková M, Chon HS, Martínez-Garcia J, Pisano C, Berek JS, Romero I, Scambia G, Fariñas-Madrid L, Buscema J, Schochter F, Li K, Kalyanapu P, Walker CJ, Vergote I.

    Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.

    GYNECOLOGIC ONCOLOGY . 185: 202-211.

    [doi:10.1016/j.ygyno.2024.05.016]

  • Agarwal N, Castellano D, Alonso-Gordoa T, Arranz Arija JA, Colomba E, Gravis G, Mourey L, Oudard S, Fléchon A, Gonzalez M, Maroto PM, Schweizer MT, Gallardo E, Johnston E, Balar A, Haddad N, Appiah AK, Nacerddine K, Piulats JM.

    A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.

    CLINICAL CANCER RESEARCH . 30(11): 2377-2383.

    [doi:10.1158/1078-0432.CCR-23-3436]

  • Fernández-Miranda I, Pedrosa L, González-Rincón J, Espinet B, de la Cruz Vicente F, Climent F, Gómez S, Royuela A, Camacho FI, Martín-Acosta P, Yanguas-Casás N, Domínguez M, Méndez M, Colomo L, Salar A, Horcajo B, Navarro M, García-Cosío M, Piris-Villaespesa M, Llanos M, García JF, Sequero S, Mercadal S, García-Hernández S, Navarro B, Mollejo M, Provencio M, Sánchez-Beato M.

    Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma.

    MODERN PATHOLOGY . 37(7): 100516-100516. Nº de citas: 2

    [doi:10.1016/j.modpat.2024.100516]

  • Borque-Fernando Á, Zapatero A, Manneh R, Alonso-Gordoa T, Couñago F, Domínguez-Esteban M, López-Valcárcel M, Rodríguez-Antolín A, Sala-González N, Sanmamed N, Maroto P.

    Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection.

    Actas Urologicas Espanolas . 48(9): 623-631.

    [doi:10.1016/j.acuroe.2024.05.008]

  • Schettini F, Blondeaux E, Molinelli C, Bas R, Kim HJ, Di Meglio A, Bernstein Molho R, Linn SC, Pogoda K, Carrasco E, Punie K, Agostinetto E, Lopetegui-Lia N, Phillips KA, Toss A, Rousset-Jablonski C, Acheritogaray M, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Vasconcelos de Matos L, Mariño M, Teixeira L, Graffeo R, Rognone A, Chirco A, Antone N, Abdou Y, Marhold M, Božovic-Spasojevic I, Cortés Salgado A, Carmisciano L, Bruzzone M, Curigliano G, Prat A, Lambertini M.

    Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.

    CANCER . 130(16): 2746-2762.

    [doi:10.1002/cncr.35323]

  • González-Martínez S, Kajabova VH, Pérez-Mies B, Carretero-Barrio I, Caniego-Casas T, Sarrió D, Moreno-Bueno G, Gión M, Perez-García J, Cortés J, Smolkova B, Palacios J.

    CDH1 methylation analysis in invasive lobular breast carcinomas with and without gene mutation.

    VIRCHOWS ARCHIV . 485(2): 291-297.

    [doi:10.1007/s00428-024-03814-8]